Halozyme Therapeutics, Inc.
HALOStock
$77.54+33.96%52W
Market Cap$9.13B
P/E28.81x
Div yield—
Beta0.86
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-8.51%
Price vs S&P 500 (4W)8.28%
VGM Score58.79
Market Capitalization$9.13B
P/E Ratio (Annual)28.81x
Earnings Surprise History
Q1 261.60est. 1.56
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.80
3.80
3.75
3.75
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HALOHalozyme Therapeutics, Inc. | C | B | B | $77.54 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Halozyme Therapeutics develops oncology therapies that target human enzymes to alter tumor progression. The company advances its pipeline through both internal development and partnerships with biopharmaceutical companies to commercialize its proprietary technology. Operations are primarily US-based with minimal international assets.